Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Press releaseGlobeNewswire· May 13, 2026

Aptose Reports First Quarter 2026 Results

“Cash and restricted cash $4,105 ... ($ in thousands) ... March 31, 2026. Total cash and restricted cash as of March 31, 2026 was $4.1 million.”

Verbatim excerpt from the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

TUS+VEN+AZA triplet is being developed as a safe and mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients ineligible to receive induction chemotherapy
60% confidence
The expected acquisition of Aptose by Hanmi Pharmaceutical will allow continued development of tuspetinib for AML patients, including those with TP53-mutated disease
60% confidence
Aptose is actively deploying cost reduction efforts to extend cash runway
60% confidence
The first two dose cohorts at 40mg and 80mg of TUS in the TUS+VEN+AZA triplet demonstrated safety, complete remissions, and MRD negativity across patients with diverse mutations including TP53-mutated/CK AML and FLT3-wildtype AML
60% confidence
Aptose does not have sufficient cash to fund operations and relies on advances made by Hanmi to fund operations
60% confidence
Parties do not anticipate that Korean regulatory reviews will prevent the closing of the Hanmi acquisition arrangement
60% confidence
TUSCANY clinical trial of tuspetinib in combination with venetoclax and azacitidine continues to deliver robust safety and response data
60% confidence